BNP Paribas Financial Markets Sells 6,291 Shares of The Cooper Companies, Inc. $COO

Key Points

• BNP Paribas Financial Markets reduced its stake in The Cooper Companies by 1.8%, selling 6,291 shares, leaving it with approximately 338,209 shares, valued at $28.5 million.
• The Cooper Companies reported a quarterly earnings per share (EPS) of $1.10, exceeding analysts' expectations of $1.07, with revenue of $1.06 billion for the quarter, reflecting a 5.7% increase year-over-year.
• Wall Street analysts have mixed ratings on the stock, with one strong buy, nine buys, and two holds, and an overall consensus price target of $86.64.

BNP Paribas Financial Markets lowered its position in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 1.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 338,209 shares of the medical device company's stock after selling 6,291 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.17% of Cooper Companies worth $28,528,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Lido Advisors LLC increased its position in Cooper Companies by 14.2% in the 4th quarter. Lido Advisors LLC now owns 3,364 shares of the medical device company's stock valued at $309,000 after acquiring an additional 419 shares in the last quarter. Baker Avenue Asset Management LP acquired a new stake in Cooper Companies in the 4th quarter valued at about $213,000. Castlekeep Investment Advisors LLC acquired a new stake in Cooper Companies in the 4th quarter valued at about $685,000. Captrust Financial Advisors increased its position in Cooper Companies by 19.0% in the 4th quarter. Captrust Financial Advisors now owns 4,542 shares of the medical device company's stock valued at $418,000 after acquiring an additional 726 shares in the last quarter. Finally, Bridgefront Capital LLC acquired a new stake in Cooper Companies in the 4th quarter valued at about $989,000. Institutional investors and hedge funds own 24.39% of the company's stock.

Cooper Companies Trading Up 0.1%

Shares of NASDAQ:COO traded up $0.09 during trading on Friday, hitting $68.09. 2,759,386 shares of the company's stock were exchanged, compared to its average volume of 2,951,187. The Cooper Companies, Inc. has a 1-year low of $61.78 and a 1-year high of $112.38. The firm has a 50-day moving average price of $71.99 and a two-hundred day moving average price of $76.65. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. The firm has a market cap of $13.54 billion, a P/E ratio of 33.54, a PEG ratio of 1.72 and a beta of 0.97.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, topping the consensus estimate of $1.07 by $0.03. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The company had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.06 billion. During the same quarter in the previous year, the company earned $0.96 EPS. Cooper Companies's revenue was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Equities analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Insider Activity

In other news, COO Gerard H. Warner III acquired 1,450 shares of Cooper Companies stock in a transaction that occurred on Friday, September 5th. The shares were acquired at an average price of $69.23 per share, with a total value of $100,383.50. Following the purchase, the chief operating officer directly owned 18,319 shares of the company's stock, valued at $1,268,224.37. The trade was a 8.60% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Brian G. Andrews acquired 1,525 shares of Cooper Companies stock in a transaction that occurred on Tuesday, September 2nd. The shares were purchased at an average cost of $65.68 per share, for a total transaction of $100,162.00. Following the purchase, the executive vice president directly owned 22,191 shares in the company, valued at $1,457,504.88. The trade was a 7.38% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 15,975 shares of company stock worth $1,079,566 over the last quarter. 1.98% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. BNP Paribas upgraded shares of Cooper Companies from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 22nd. JPMorgan Chase & Co. lowered their price objective on shares of Cooper Companies from $76.00 to $66.00 and set a "neutral" rating for the company in a research report on Thursday, August 28th. Morgan Stanley set a $76.00 price objective on shares of Cooper Companies and gave the company an "equal weight" rating in a research report on Thursday, August 28th. UBS Group upgraded shares of Cooper Companies to a "buy" rating in a research report on Tuesday, June 17th. Finally, Piper Sandler lowered their price target on shares of Cooper Companies from $105.00 to $83.00 and set an "overweight" rating for the company in a research report on Thursday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $86.64.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.